Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Comprar returned no results
Showing 421 to 435 of 555 results for compare

  1. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

    Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    14 August 2019
    View recommendations

    Sections for TA595

  2. Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA676

  3. Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)

    Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.

    Technology appraisal guidance
    Published
    28 May 2025

    Sections for TA1065

  4. BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis (MIB32)

    NICE has developed a medtech innovation briefing (MIB) on BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis .

    Medtech innovation briefing
    Published
    21 July 2015

  5. The PolySoft hernia patch used with the ONSTEP technique to treat inguinal hernias (MIB9)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Polysoft hernia patch for use with the ONSTEP technique to treat inguinal hernias

    Medtech innovation briefing
    Published
    26 August 2014

  6. eazyplex SuperBug kits for detecting carbapenemase-producing organisms (MIB94)

    NICE has developed a medtech innovation briefing (MIB) on eazyplex SuperBug kits for detecting carbapenemase-producing organisms .

    Medtech innovation briefing
    Published
    7 February 2017

  7. Melanoma: assessment and management (NG14)

    This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

    NICE guideline
    Last updated
    27 July 2022
    View recommendations

    Sections for NG14

  8. End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

    This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.

    NICE guideline
    Last updated
    25 July 2019
    View recommendations

    Sections for NG61

  9. Social media:- How effective are online social media and networks at improving health and wellbeing and reducing health inequalities when they are used:- as a method of community engagement?- to support an existing community engagement approach?

    delivering initiatives. In particular, there's a lack of evidence on how its use compares with face-to-face approaches. In addition, it...

    Research recommendation
    Published
    7 April 2016

  10. Physiotherapy:- Does physiotherapy started early in the course of Parkinson's disease, as opposed to after motor symptom onset, confer benefits in terms of delaying symptom onset and/or reducing severity?

    Parkinson's disease and their family and carers. Relevant trials would not compare physiotherapy with no physiotherapy, but rather early...

    Research recommendation
    Published
    15 October 2018

  11. In well-defined generalised anxiety disorder (GAD), what is the clinical and cost effectiveness of two cognitive behavioural therapy (CBT) based low-intensity interventions (CCBT and guided bibliotherapy) compared with a waiting-list control?

    and cost-effective treatment that should be provided for GAD, and how it compares with other low-intensity interventions such as guided...

    Research recommendation
    Published
    9 June 2015

  12. In well-defined panic disorder, what is the clinical and cost effectiveness of two cognitive behavioural therapy (CBT) based low-intensity interventions (CCBT and guided bibliotherapy) compared with a waiting-list control?

    cost-effective treatment that should be provided for panic disorder, and how it compares with other low-intensity interventions such as...

    Research recommendation
    Published
    9 June 2015

  13. Morphine compared with ketamine for first-line management of pain:- Is morphine clinically and cost effective compared with ketamine for first-line pharmacological pain management (in both pre-hospital and hospital settings) in patients with major trauma?

    However, there is little evidence from well-controlled trials that directly compares the effectiveness and side effects of morphine and...

    Research recommendation
    Published
    21 March 2016

  14. Cost effectiveness of daycare units for treating patients with an acute painful sickle cell episode:- Are daycare units cost effective compared with emergency settings for treating patients with an acute painful sickle cell episode?

    painful sickle cell episode in the UK. A trial should be carried out that compares treating patients with an acute painful sickle cell...

    Research recommendation
    Published
    9 June 2015

  15. Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

    Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA807